Trial intelligence / Profile preview

Dasatinib Maintenance After Allogeneic HSCT in Ph+ ALL (DASALL II)

jRCTs031180213Phase 2Completed

Sponsor

Bristol Myers Squibb

Start

Feb 2017

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

2